{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.6","upperLimit":"15.6","value":"11.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive dabrafenib mesylate 150 mg PO BID and trametinib dimethyl sulfoxide 2 mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Dabrafenib, Trametinib)"}],"paramType":"MEDIAN","populationDescription":"Eligible, treated and mutation status confirmed","reportingStatus":"POSTED","timeFrame":"Assessed at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration","title":"Progression-Free Survival","type":"SECONDARY","unitOfMeasure":"months"}